Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies

References

• Ma X, Yu H. Global burden of cancer. Yale J Biol Med. 2006;79(3–4):85–94.
   PubMedGoogle Scholar
• Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Guevara-Patiño JA, Turk MJ, Wolchok JD, Houghton AN. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res. 2003;90:157–177.
   PubMed Web of Science ®Google Scholar
• Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. doi:10.1186/s13045-019-0787-5
   PubMed Web of Science ®Google Scholar
• Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol. 2018;9(14). doi:10.3389/fimmu.2018.00014
   Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. doi:10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 2011;93(3):294–300. doi:10.1007/s12185-011-0799-6
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Karmakar S, Lal G. Role of serotonin receptor signaling in cancer cells and anti-tumor immunity. Theranostics. 2021;11(11):5296–5312. doi:10.7150/thno.55986
   Web of Science ®Google Scholar
• Paul S, Kulkarni N, Shilpi LG, Lal G. Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. Oncoimmunology. 2016;5(12):e1235106. doi:10.1080/2162402X.2016.1235106
   PubMed Web of Science ®Google Scholar
• Muntasell A, Ochoa MC, Cordeiro L, et al. Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol. 2017;45:73–81. doi:10.1016/j.coi.2017.01.003
   PubMed Web of Science ®Google Scholar
• Lorenzo-Herrero S, López-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, Gonzalez S. NK cell-based immunotherapy in cancer metastasis. Cancers. 2018;11(1):29. doi:10.3390/cancers11010029
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510. doi:10.1038/ni1582
   PubMed Web of Science ®Google Scholar
• Huntington ND, Vosshenrich CAJ, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7(9):703–714. doi:10.1038/nri2154
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869. doi:10.3389/fimmu.2018.01869
   PubMed Web of Science ®Google Scholar
• Bozzano F, Marras F, De Maria A. Natural killer cell development and maturation revisited: possible implications of a novel distinct Lin−CD34+DNAM-1brightCXCR4+ cell progenitor. Front Immunol. 2017;8(268). doi:10.3389/fimmu.2017.00268
   Web of Science ®Google Scholar
• Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11(10):645–657. doi:10.1038/nri3044
   PubMed Web of Science ®Google Scholar
• Peng H, Jiang X, Chen Y, et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest. 2013;123(4):1444–1456. doi:10.1172/JCI66381
   Web of Science ®Google Scholar
• Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology. 2013;57(4):1654–1662. doi:10.1002/hep.26115
   PubMed Web of Science ®Google Scholar
• Fu B, Tian Z, Wei H. Subsets of human natural killer cells and their regulatory effects. Immunology. 2014;141(4):483–489. doi:10.1111/imm.12224
   Web of Science ®Google Scholar
• O’Sullivan Timothy E, Sun Joseph C, Lanier Lewis L. Natural killer cell memory. Immunity. 2015;43(4):634–645. doi:10.1016/j.immuni.2015.09.013
   Web of Science ®Google Scholar
• Fehniger TA, Cooper MA. Harnessing NK cell memory for cancer immunotherapy. Trends Immunol. 2016;37(12):877–888. doi:10.1016/j.it.2016.09.005
   PubMed Web of Science ®Google Scholar
• Beaulieu AM. Transcriptional and epigenetic regulation of memory NK cell responses. Immunol Rev. 2021;300(1):125–133. doi:10.1111/imr.12947
   PubMed Web of Science ®Google Scholar
• Forrest C, Gomes A, Reeves M, Male V. NK cell memory to cytomegalovirus: implications for vaccine development. Vaccines (Basel). 2020;8(3). doi:10.3390/vaccines8030394
   Web of Science ®Google Scholar
• Wight A, Parsons BD, Rahim MMA, Makrigiannis AP. A central role for Ly49 receptors in NK cell memory. J Immunol. 2020;204(11):2867–2875. doi:10.4049/jimmunol.2000196
   Web of Science ®Google Scholar
• Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227–258. doi:10.1146/annurev-immunol-020711-075005
   PubMed Web of Science ®Google Scholar
• Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009;128(1):7–15. doi:10.1111/j.1365-2567.2009.03123.x
   PubMed Web of Science ®Google Scholar
• Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8(1124). doi:10.3389/fimmu.2017.01124
   Web of Science ®Google Scholar
• Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10(1205). doi:10.3389/fimmu.2019.01205
   Web of Science ®Google Scholar
• Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. doi:10.1186/s12943-020-01238-x
   PubMed Web of Science ®Google Scholar
• Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6(368). doi:10.3389/fimmu.2015.00368
   Web of Science ®Google Scholar
• Sanseviero E. NK cell-Fc receptors advance tumor immunotherapy. J Clin Med. 2019;8(10):1667. doi:10.3390/jcm8101667
   Web of Science ®Google Scholar
• Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 2012;14(3):247–261. doi:10.1016/j.micinf.2011.10.006
   PubMed Web of Science ®Google Scholar
• Poznanski SM, Lee AJ, Nham T, et al. Combined stimulation with interleukin-18 and interleukin-12 potently induces interleukin-8 production by natural killer cells. J Innate Immun. 2017;9(5):511–525. doi:10.1159/000477172
   Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1):15–22. doi:10.1016/j.jim.2004.08.008
   Web of Science ®Google Scholar
• Krebs P, Barnes MJ, Lampe K, et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood. 2009;113(26):6593–6602. doi:10.1182/blood-2009-01-201467
   Web of Science ®Google Scholar
• Pardo J, Balkow S, Anel A, Simon MM. Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. Eur J Immunol. 2002;32(10):2881–2886. doi:10.1002/1521-4141(2002010)32:10<2881::AID-IMMU2881>3.0.CO;2-K
   Web of Science ®Google Scholar
• Sonar S, Lal G. Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity. Front Immunol. 2015;6(364). doi:10.3389/fimmu.2015.00364
   Web of Science ®Google Scholar
• Screpanti V, Wallin RPA, Ljunggren H-G, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 2001;167(4):2068–2073. doi:10.4049/jimmunol.167.4.2068
   PubMed Web of Science ®Google Scholar
• Thorburn A. Death receptor-induced cell killing. Cell Signal. 2004;16(2):139–144. doi:10.1016/j.cellsig.2003.08.007
   PubMed Web of Science ®Google Scholar
• Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology. 2009;126(4):449–457. doi:10.1111/j.1365-2567.2009.03045.x
   PubMed Web of Science ®Google Scholar
• Wensveen FM, Jelenčić V, Polić B. NKG2D: a master regulator of immune cell responsiveness. Front Immunol. 2018;9(441). doi:10.3389/fimmu.2018.00441
   Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727–729. doi:10.1126/science.285.5428.727
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer. 2003;104(3):354–361. doi:10.1002/ijc.10966
   PubMed Web of Science ®Google Scholar
• Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci. 1996;93(22):12445–12450. doi:10.1073/pnas.93.22.12445
   PubMed Web of Science ®Google Scholar
• Romanski A, Bug G, Becker S, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol. 2005;33(3):344–352. doi:10.1016/j.exphem.2004.11.006
   Web of Science ®Google Scholar
• Sconocchia G, Lau M, Provenzano M, et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D–target-cell interactions. Blood. 2005;106(10):3666–3672. doi:10.1182/blood-2005-02-0479
   Web of Science ®Google Scholar
• Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251–258. doi:10.1182/blood-2004-04-1422
   Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389–1396. doi:10.1182/blood-2003-01-0019
   PubMed Web of Science ®Google Scholar
• Pende D, Sivori S, Accame L, et al. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. Eur J Immunol. 1997;27(8):1875–1880. doi:10.1002/eji.1830270809
   Web of Science ®Google Scholar
• Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science. 2001;294(5542):605–609. doi:10.1126/science.1063916
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Swann J, Kelly JM, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med. 2004;200(10):1325–1335. doi:10.1084/jem.20041522
   PubMed Web of Science ®Google Scholar
• Lowin-Kropf B, Kunz B, Schneider P, Held W. A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. Eur J Immunol. 2002;32(3):773–782. doi:10.1002/1521-4141(200203)32:3<773::AID-IMMU773>3.0.CO;2-U
   Web of Science ®Google Scholar
• Coudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol. 2006;16(5):333–343. doi:10.1016/j.semcancer.2006.07.008
   Web of Science ®Google Scholar
• Schenkel AR, Kingry LC, Slayden RA. The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection. Front Immunol. 2013;4:90. doi:10.3389/fimmu.2013.00090
   Web of Science ®Google Scholar
• Smith HRC, Heusel JW, Mehta IK, et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci. 2002;99(13):8826–8831. doi:10.1073/pnas.092258599
   PubMed Web of Science ®Google Scholar
• Silver ET, Gong D-E, Hazes B, Kane KP. Ly-49W, an activating receptor of nonobese diabetic mice with close homology to the inhibitory receptor Ly-49G, recognizes H-2Dk and H-2Dd. J Immunol. 2001;166(4):2333–2341. doi:10.4049/jimmunol.166.4.2333
   Web of Science ®Google Scholar
• Silver ET, Gong D-E, Chang CS, Amrani A, Santamaria P, Kane KP. Ly-49P activates NK-mediated lysis by recognizing H-2Dd1. J Immunol. 2000;165(4):1771–1781. doi:10.4049/jimmunol.165.4.1771
   Web of Science ®Google Scholar
• Nakamura MC, Linnemeyer PA, Niemi EC, et al. Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity. J Exp Med. 1999;189(3):493–500. doi:10.1084/jem.189.3.493
   Web of Science ®Google Scholar
• Merck E, Voyle RB, MacDonald HR. Ly49D engagement on T lymphocytes induces TCR-independent activation and CD8 effector functions that control tumor growth. J Immunol. 2009;182(1):183–192. doi:10.4049/jimmunol.182.1.183
   Web of Science ®Google Scholar
• Gao J-X, Liu X, Wen J, et al. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood. 2004;102:4456–4463. doi:10.1182/blood-2003-07-2480
   Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218. doi:10.1038/s41573-019-0052-1
   PubMed Web of Science ®Google Scholar
• Vaidya SV, Stepp SE, McNerney ME, et al. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol. 2005;174(2):800–807. doi:10.4049/jimmunol.174.2.800
   Web of Science ®Google Scholar
• Lee K-M, McNerney ME, Stepp SE, et al. 2B4 acts as a non–major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med. 2004;199(9):1245–1254. doi:10.1084/jem.20031989
   PubMed Web of Science ®Google Scholar
• Tangye SG, Cherwinski H, Lanier LL, Phillips JH. 2B4-mediated activation of human natural killer cells. Mol Immunol. 2000;37(9):493–501. doi:10.1016/S0161-5890(00)00076-6
   Web of Science ®Google Scholar
• Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol. 1999;162(12):6981–6985.
   Web of Science ®Google Scholar
• Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol. 2019;10:909. doi:10.3389/fimmu.2019.00909
   PubMed Web of Science ®Google Scholar
• Pogge von Strandmann E, Shatnyeva O, Hansen HP. NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells. Ann Transl Med. 2015;3(20):2305–5839.
   Google Scholar
• Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206(7):1495–1503. doi:10.1084/jem.20090681
   PubMed Web of Science ®Google Scholar
• Töpfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201–3212. doi:10.4049/jimmunol.1400330
   PubMed Web of Science ®Google Scholar
• Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–192. doi:10.1016/j.stem.2018.06.002
   PubMed Web of Science ®Google Scholar
• Rah S-Y, Kwak J-Y, Chung Y-J, Kim U-H. ADP-ribose/TRPM2-mediated Ca2+ signaling is essential for cytolytic degranulation and antitumor activity of natural killer cells. Sci Rep. 2015;5(1):9482. doi:10.1038/srep09482
   Web of Science ®Google Scholar
• Mallone R, Funaro A, Zubiaur M, et al. Signaling through CD38 induces NK cell activation. Int Immunol. 2001;13(4):397–409. doi:10.1093/intimm/13.4.397
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216–224. doi:10.1038/icb.2010.78
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Burke S, Ali TH, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009;119(5):1251–1263. doi:10.1172/JCI36022
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Morgado S, Gayoso I, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother. 2011;60(8):1195–1205. doi:10.1007/s00262-011-1050-2
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Bertucci F, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71(21):6621–6632. doi:10.1158/0008-5472.CAN-11-0792
   PubMed Web of Science ®Google Scholar
• Mirjačić Martinović KM, Babović N, Džodić RR, Jurišić VB, Tanić NT, Konjević GM. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res. 2014;24(4):295–304. doi:10.1097/CMR.0000000000000072
   Web of Science ®Google Scholar
• Zhang C, Hu Y, Shi C. Targeting natural killer cells for tumor immunotherapy. Front Immunol. 2020;11:60.
   PubMed Web of Science ®Google Scholar
• Balsamo M, Scordamaglia F, Pietra G, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(49):20847–20852. doi:10.1073/pnas.0906481106
   PubMed Web of Science ®Google Scholar
• Lanier LL. Natural killer cell receptor signaling. Curr Opin Immunol. 2003;15(3):308–314. doi:10.1016/S0952-7915(03)00039-6
   PubMed Web of Science ®Google Scholar
• Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood. 1998;91(7):2369–2380. doi:10.1182/blood.V91.7.2369
   Web of Science ®Google Scholar
• Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med. 2002;80(4):248–257. doi:10.1007/s00109-001-0294-2
   Web of Science ®Google Scholar
• Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675–678. doi:10.1038/319675a0
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237–244. doi:10.1016/0167-5699(90)90097-s
   PubMedGoogle Scholar
• Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018;154(3):383–393. doi:10.1111/imm.12921
   PubMed Web of Science ®Google Scholar
• Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008;224:70–84. doi:10.1111/j.1600-065X.2008.00660.x
   PubMed Web of Science ®Google Scholar
• Rajasekaran K, Riese MJ, Rao S, et al. Signaling in effector lymphocytes: insights toward safer immunotherapy. Front Immunol. 2016;7:176. doi:10.3389/fimmu.2016.00176
   PubMed Web of Science ®Google Scholar
• Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430–441. doi:10.1038/s41423-019-0206-4
   PubMed Web of Science ®Google Scholar
• Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–251. doi:10.1146/annurev.immunol.20.092501.134942
   PubMed Web of Science ®Google Scholar
• Braud VM, Allan DS, O’Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795–799. doi:10.1038/35869
   PubMed Web of Science ®Google Scholar
• Moretta L. Dissecting CD56dim human NK cells. Blood. 2010;116(19):3689–3691. doi:10.1182/blood-2010-09-303057
   PubMed Web of Science ®Google Scholar
• Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230–252. doi:10.1038/cmi.2013.10
   PubMed Web of Science ®Google Scholar
• Andre P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–1743 e13. doi:10.1016/j.cell.2018.10.014
   PubMed Web of Science ®Google Scholar
• Mingari MC, Ponte M, Bertone S, et al. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci USA. 1998;95(3):1172–1177. doi:10.1073/pnas.95.3.1172
   Web of Science ®Google Scholar
• Bertone S, Schiavetti F, Bellomo R, et al. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol. 1999;29(1):23–29. doi:10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y
   Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–469. doi:10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Hammer Q, Ruckert T, Borst EM, et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018;19(5):453–463. doi:10.1038/s41590-018-0082-6
   PubMed Web of Science ®Google Scholar
• Della Chiesa M, Sivori S, Carlomagno S, Moretta L, Moretta A. Activating KIRs and NKG2C in viral infections: toward NK cell memory? Front Immunol. 2015;6:573. doi:10.3389/fimmu.2015.00573
   Web of Science ®Google Scholar
• Colonna M, Navarro F, Bellon T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186(11):1809–1818. doi:10.1084/jem.186.11.1809
   PubMed Web of Science ®Google Scholar
• Ponte M, Cantoni C, Biassoni R, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A. 1999;96(10):5674–5679. doi:10.1073/pnas.96.10.5674
   PubMed Web of Science ®Google Scholar
• Cosman D, Fanger N, Borges L, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7(2):273–282. doi:10.1016/s1074-7613(00)80529-4
   PubMed Web of Science ®Google Scholar
• Vitale M, Castriconi R, Parolini S, et al. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int Immunol. 1999;11(1):29–35. doi:10.1093/intimm/11.1.29
   Web of Science ®Google Scholar
• Muccio L, Bertaina A, Falco M, et al. Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing alphabeta+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica. 2016;101(3):371–381. doi:10.3324/haematol.2015.134155
   Web of Science ®Google Scholar
• Fong JJ, Tsai CM, Saha S, Nizet V, Varki A, Bui JD. Siglec-7 engagement by GBS beta-protein suppresses pyroptotic cell death of natural killer cells. Proc Natl Acad Sci U S A. 2018;115(41):10410–10415. doi:10.1073/pnas.1804108115
   PubMed Web of Science ®Google Scholar
• Murakami Y, Tian L, Voss OH, Margulies DH, Krzewski K, Coligan JE. CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition. Cell Death Differ. 2014;21(11):1746–1757. doi:10.1038/cdd.2014.86
   PubMed Web of Science ®Google Scholar
• Sivori S, Della Chiesa M, Carlomagno S, et al. Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of cancer. Front Immunol. 2020;11:2156. doi:10.3389/fimmu.2020.02156
   PubMed Web of Science ®Google Scholar
• Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28(28):4390–4399. doi:10.1200/JCO.2009.27.6360
   PubMed Web of Science ®Google Scholar
• Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol. 2016;1441:3684–7_28.
   PubMedGoogle Scholar
• Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol Res. 2018;6(7):776–787. doi:10.1158/2326-6066.CIR-17-0649
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024–4031. doi:10.1182/blood-2014-12-614636
   PubMed Web of Science ®Google Scholar
• Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8(1):96. doi:10.1186/s13045-015-0188-3
   PubMed Web of Science ®Google Scholar
• Pahl JHW, Koch J, Götz JJ, et al. CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. Cancer Immunol Res. 2018;6(5):517–527. doi:10.1158/2326-6066.CIR-17-0550
   PubMed Web of Science ®Google Scholar
• Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol. 2017;31:64–75. doi:10.1016/j.smim.2017.07.011
   PubMed Web of Science ®Google Scholar
• Felices M, Kodal B, Hinderlie P, et al. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv. 2019;3(6):897–907. doi:10.1182/bloodadvances.2018029371
   PubMed Web of Science ®Google Scholar
• Vallera DA, Felices M, McElmurry R, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res. 2016;22(14):3440–3450. doi:10.1158/1078-0432.CCR-15-2710
   PubMed Web of Science ®Google Scholar
• Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther. 2016;24(7):1312–1322. doi:10.1038/mt.2016.88
   PubMed Web of Science ®Google Scholar
• Gauthier L, Morel A, Anceriz N, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019;177(7):1701–1713. doi:10.1016/j.cell.2019.04.041
   PubMed Web of Science ®Google Scholar
• Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49–57. doi:10.1182/blood-2017-06-741041
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929–1936. doi:10.1158/1078-0432.CCR-16-1272
   PubMed Web of Science ®Google Scholar
• Segal NH, He AR, Doi T, et al. Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin Cancer Res. 2018;24(8):1816–1823. doi:10.1158/1078-0432.CCR-17-1922
   PubMed Web of Science ®Google Scholar
• Ferrari de Andrade L, Tay RE, Pan D, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018;359(6383):1537–1542. doi:10.1126/science.aao0505
   PubMed Web of Science ®Google Scholar
• Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 2011;3(12):1445–1459. doi:10.2217/imt.11.131
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi:10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Calvo T, Reina-Ortiz C, Giraldos D, et al. Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Sci Rep. 2020;10(1):19398. doi:10.1038/s41598-020-76051-z
   Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–3057. doi:10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Prlic M, Blazar BR, Farrar MA, Jameson SC. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med. 2003;197(8):967–976. doi:10.1084/jem.20021847
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol. 2001;20(3–4):503–534. doi:10.3109/08830180109054417
   PubMedGoogle Scholar
• Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98–107. doi:10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;15(3):e28147.
   Web of Science ®Google Scholar
• Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018;39(2):167–176. doi:10.1038/aps.2017.125
   PubMed Web of Science ®Google Scholar
• Oei VYS, Siernicka M, Graczyk-Jarzynka A, et al. Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors. Cancer Immunol Res. 2018;6(4):467–480. doi:10.1158/2326-6066.CIR-17-0207
   PubMed Web of Science ®Google Scholar
• Zhuang X, Long EO. CD28 homolog is a strong activator of natural killer cells for lysis of B7H7(+) tumor cells. Cancer Immunol Res. 2019;7(6):939–951.
   Web of Science ®Google Scholar
• Marofi F, Saleh MM, Rahman HS, et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther. 2021;12(1):374. doi:10.1186/s13287-021-02462-y
   PubMed Web of Science ®Google Scholar
• Wilson MH, Coates CJ, George AL. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther. 2007;15(1):139–145. doi:10.1038/sj.mt.6300028
   PubMed Web of Science ®Google Scholar
• Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer. 2018;6(1):018–0441. doi:10.1186/s40425-018-0441-8
   Web of Science ®Google Scholar
• Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777–1786. doi:10.1158/0008-5472.CAN-12-3558
   PubMed Web of Science ®Google Scholar
• Parihar R, Rivas C, Huynh M, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7(3):363–375. doi:10.1158/2326-6066.CIR-18-0572
   PubMed Web of Science ®Google Scholar
• Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–531. doi:10.1038/leu.2017.226
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376–383. doi:10.1182/blood-2004-12-4797
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2010;17(3):147–154. doi:10.1038/cgt.2009.61
   PubMed Web of Science ®Google Scholar
• Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769–1781. doi:10.1016/j.ymthe.2017.06.012
   PubMed Web of Science ®Google Scholar
• Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018;17:4054815. doi:10.1155/2018/4054815
   Web of Science ®Google Scholar
• Woll PS, Grzywacz B, Tian X, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009;113(24):6094–6101. doi:10.1182/blood-2008-06-165225
   PubMed Web of Science ®Google Scholar
• Knorr DA, Bock A, Brentjens RJ, Kaufman DS. Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem Cells Dev. 2013;22(13):1861–1869. doi:10.1089/scd.2012.0608
   Web of Science ®Google Scholar
• Knorr DA, Ni Z, Hermanson D, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274–283. doi:10.5966/sctm.2012-0084
   PubMed Web of Science ®Google Scholar
• Gornalusse GG, Hirata RK, Funk SE, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765–772. doi:10.1038/nbt.3860
   PubMed Web of Science ®Google Scholar
• Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59(102975):24. doi:10.1016/j.ebiom.2020.102975
   Web of Science ®Google Scholar
• Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159–166. doi:10.1182/blood-2005-04-1351
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20(4):463–473. doi:10.1016/j.bbmt.2014.01.006
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357). doi:10.1126/scitranslmed.aaf2341.
   Web of Science ®Google Scholar
• Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012;209(13):2351–2365. doi:10.1084/jem.20120944
   Web of Science ®Google Scholar
• Cichocki F, Valamehr B, Bjordahl R, et al. GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res. 2017;77(20):5664–5675. doi:10.1158/0008-5472.CAN-17-0799
   Web of Science ®Google Scholar
• North J, Bakhsh I, Marden C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol. 2007;178(1):85–94. doi:10.4049/jimmunol.178.1.85
   Web of Science ®Google Scholar
• Fehniger TA, Miller JS, Stuart RK, et al. A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2018;24(8):1581–1589. doi:10.1016/j.bbmt.2018.03.019
   PubMed Web of Science ®Google Scholar
• Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7):1760. doi:10.3390/cancers12071760
   PubMed Web of Science ®Google Scholar
• van Montfoort N, Borst L, Korrer MJ, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018;175(7):1744–1755 e15. doi:10.1016/j.cell.2018.10.028
   PubMed Web of Science ®Google Scholar
• van Hall T, Andre P, Horowitz A, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7(1):263. doi:10.1186/s40425-019-0761-3
   PubMed Web of Science ®Google Scholar
• Graydon CG, Mohideen S, Fowke KR. LAG3’s enigmatic mechanism of action. Front Immunol. 2020;11:615317. doi:10.3389/fimmu.2020.615317
   Web of Science ®Google Scholar
• Lichtenegger FS, Rothe M, Schnorfeil FM, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol. 2018;9:385. doi:10.3389/fimmu.2018.00385
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927. doi:10.1158/0008-5472.CAN-11-1620
   PubMed Web of Science ®Google Scholar
• Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V. Recent advances in our understanding of HLA-G biology: lessons from a wide spectrum of human diseases. J Immunol Res. 2016;2016:4326495. doi:10.1155/2016/4326495
   PubMed Web of Science ®Google Scholar
• Anna F, Bole-Richard E, LeMaoult J, et al. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G. J Immunother Cancer. 2021;9(3):e001998. doi:10.1136/jitc-2020-001998
   Web of Science ®Google Scholar
• Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L. NK cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia. Trends Immunol. 2018;39(7):577–590. doi:10.1016/j.it.2018.04.009
   Web of Science ®Google Scholar
• Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113(13):3119–3129. doi:10.1182/blood-2008-06-164103
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118(12):3273–3279. doi:10.1182/blood-2011-01-329508
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411–2419. doi:10.1182/blood-2010-05-283051
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Cooley S, Wang T, et al. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020;4(4):740–754. doi:10.1182/bloodadvances.2019001053
   PubMed Web of Science ®Google Scholar
• Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–1170. doi:10.1016/S1470-2045(19)30320-1
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009;15(23):7330–7334. doi:10.1158/1078-0432.CCR-09-1720
   PubMed Web of Science ®Google Scholar
• Tarek N, Le Luduec JB, Gallagher MM, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012;122(9):3260–3270. doi:10.1172/JCI62749
   PubMed Web of Science ®Google Scholar
• Erbe AK, Wang W, Carmichael L, et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019;7(1):70. doi:10.1186/s40425-019-0538-8
   PubMed Web of Science ®Google Scholar
• Erbe AK, Wang W, Carmichael L, et al. Neuroblastoma patients’ KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the children’s oncology group. Clin Cancer Res. 2018;24(1):189–196. doi:10.1158/1078-0432.CCR-17-1767
   Web of Science ®Google Scholar
• Pesce S, Greppi M, Tabellini G, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335–346e3. doi:10.1016/j.jaci.2016.04.025
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng Y, Xu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143–6153. doi:10.1038/onc.2017.209
   PubMed Web of Science ®Google Scholar
• Beldi-Ferchiou A, Lambert M, Dogniaux S, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7(45):72961–72977. doi:10.18632/oncotarget.12150
   PubMedGoogle Scholar
• Benson DM, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–2294. doi:10.1182/blood-2010-02-271874
   PubMed Web of Science ®Google Scholar
• Quatrini L, Vacca P, Tumino N, et al. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. J Allergy Clin Immunol. 2021;147(1):349–360. doi:10.1016/j.jaci.2020.04.044
   PubMed Web of Science ®Google Scholar
• Mariotti FR, Quatrini L, Munari E, et al. Inhibitory checkpoints in human natural killer cells: IUPHAR review 28. Br J Pharmacol. 2020;177(13):2889–2903. doi:10.1111/bph.15081
   Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Sholl LM, Aisner DL, Allen TC, et al. Programmed death ligand-1 immunohistochemistry–a new challenge for pathologists: a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med. 2016;140(4):341–344. doi:10.5858/arpa.2015-0506-SA
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167. doi:10.1038/nri.2017.108
   PubMed Web of Science ®Google Scholar
• Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911. doi:10.1136/jitc-2020-000911
   PubMed Web of Science ®Google Scholar
• da Silva IP, Gallois A, Jimenez-Baranda S, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410–422. doi:10.1158/2326-6066.CIR-13-0171
   PubMed Web of Science ®Google Scholar
• Xu L, Huang Y, Tan L, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29(2):635–641. doi:10.1016/j.intimp.2015.09.017
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai P, Liang T, Wang L, Hu L. TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(19):31705–31713. doi:10.18632/oncotarget.15954
   PubMedGoogle Scholar
• Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. doi:10.1136/jitc-2020-000957
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0
   PubMed Web of Science ®Google Scholar
• Zhou XM, Li WQ, Wu YH, et al. Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8(+) T cells. Front Immunol. 2018;9:2821. doi:10.3389/fimmu.2018.02821
   PubMed Web of Science ®Google Scholar
• Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769. doi:10.1080/2162402X.2018.1466769
   PubMed Web of Science ®Google Scholar
• Shao JY, Yin WW, Zhang QF, et al. Siglec-7 defines a highly functional natural killer cell subset and inhibits cell-mediated activities. Scand J Immunol. 2016;84(3):182–190. doi:10.1111/sji.12455
   PubMed Web of Science ®Google Scholar
• Daly J, Carlsten M, O’Dwyer M. Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer. Front Immunol. 2019;10:1047. doi:10.3389/fimmu.2019.01047
   Web of Science ®Google Scholar
• Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci U S A. 2016;113(37):10304–10309. doi:10.1073/pnas.1608069113
   PubMed Web of Science ®Google Scholar
• Macauley MS, Arlian BM, Rillahan CD, et al. Systemic blockade of sialylation in mice with a global inhibitor of sialyltransferases. J Biol Chem. 2014;289(51):35149–35158. doi:10.1074/jbc.M114.606517
   PubMed Web of Science ®Google Scholar
• Bull C, Boltje TJ, Balneger N, et al. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity. Cancer Res. 2018;78(13):3574–3588. doi:10.1158/0008-5472.CAN-17-3376
   PubMed Web of Science ®Google Scholar
• Meril S, Harush O, Reboh Y, Matikhina T, Barliya T, Cohen CJ. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells. Mol Carcinog. 2020;59(7):713–723. doi:10.1002/mc.23213
   Web of Science ®Google Scholar
• Molgora M, Supino D, Mantovani A, Garlanda C. Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8. Immunol Rev. 2018;281(1):233–247. doi:10.1111/imr.12609
   PubMed Web of Science ®Google Scholar
• Molgora M, Bonavita E, Ponzetta A, et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature. 2017;551(7678):110–114. doi:10.1038/nature24293
   PubMed Web of Science ®Google Scholar
• Verbrugge A, de Ruiter T, Geest C, Coffer PJ, Meyaard L. Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation. J Leukoc Biol. 2006;79(4):828–836. doi:10.1189/jlb.0705370
   PubMed Web of Science ®Google Scholar
• Jansen CA, Cruijsen CW, de Ruiter T, et al. Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation. Eur J Immunol. 2007;37(4):914–924. doi:10.1002/eji.200636678
   PubMed Web of Science ®Google Scholar
• van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur J Immunol. 1999;29(10):3160–3167. doi:10.1002/(SICI)1521-4141(199910)29:10<3160::AID-IMMU3160>3.0.CO;2-S
   Web of Science ®Google Scholar
• Guo N, Zhang K, Gao X, et al. Role and mechanism of LAIR-1 in the development of autoimmune diseases, tumors, and malaria: a review. Curr Res Transl Med. 2020;68(3):119–124. doi:10.1016/j.retram.2020.05.003
   Web of Science ®Google Scholar
• Peng DH, Rodriguez BL, Diao L, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat Commun. 2020;11(1):4520. doi:10.1038/s41467-020-18298-8
   PubMed Web of Science ®Google Scholar
• Meyaard L, Adema GJ, Chang C, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 1997;7(2):283–290. doi:10.1016/s1074-7613(00)80530-0
   PubMed Web of Science ®Google Scholar
• Joseph C, Alsaleem MA, Toss MS, et al. The ITIM-containing receptor: leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) modulates immune response and confers poor prognosis in invasive breast carcinoma. Cancers (Basel). 2020;13(1):80. doi:10.3390/cancers13010080
   Web of Science ®Google Scholar
• Nakamura S, Kuroki K, Ohki I, et al. Molecular basis for E-cadherin recognition by killer cell lectin-like receptor G1 (KLRG1). J Biol Chem. 2009;284(40):27327–27335. doi:10.1074/jbc.M109.038802
   Web of Science ®Google Scholar
• Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Ann Rev Cancer Biol. 2019;3(1):77–103. doi:10.1146/annurev-cancerbio-030518-055653
   Google Scholar
• Tata A, Vivier E, Brossay L. Role of the KLRG1 pathway during the immune response to cancer. J Immunol. 2020;204(1Supplement):88.8.
   Google Scholar
• Greenberg SA, Kong SW, Thompson E, Gulla SV. Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. Oncotarget. 2019;10(14):1399–1406. doi:10.18632/oncotarget.26659
   PubMedGoogle Scholar
• Tata A, Dodard G, Fugere C, et al. Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers. Oncoimmunology. 2021;10(1):1933808. doi:10.1080/2162402X.2021.1933808
   Web of Science ®Google Scholar
• Cantoni C, Bottino C, Augugliaro R, et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol. 1999;29(10):3148–3159. doi:10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L
   Web of Science ®Google Scholar
• Birge RB, Boeltz S, Kumar S, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016;23(6):962–978. doi:10.1038/cdd.2016.11
   PubMed Web of Science ®Google Scholar
• Lankry D, Rovis TL, Jonjic S, Mandelboim O. The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur J Immunol. 2013;43(8):2151–2161. doi:10.1002/eji.201343433
   PubMed Web of Science ®Google Scholar
• Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F. Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood. 2012;119(12):2799–2809. doi:10.1182/blood-2011-08-372425
   PubMed Web of Science ®Google Scholar
• Sun X, Huang S, Wang X, Zhang X, Wang X. CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. Oncotarget. 2018;9(44):27574–27584. doi:10.18632/oncotarget.24164
   PubMedGoogle Scholar
• Jiang L, Xu Y, Zeng X, Fang J, Morse HC, Zhou JX. Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget. 2015;6(31):31191–31202. doi:10.18632/oncotarget.5152
   PubMedGoogle Scholar